Kite presents new data underscoring curative potential of yescarta® in relapsed/refractory large b-cell lymphoma at ash

Santa monica, calif.--(business wire)--kite, a gilead company (nasdaq: gild), today announced findings from three new analyses for yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (r/r) large b-cell lymphoma (lbcl), which were presented at 66th american society of hematology (ash) annual meeting & exposition. the data include findings from the largest real-world analysis of patients who received yescarta as second-line trea.
ASH Ratings Summary
ASH Quant Ranking